Skip to main content

Collagen and the Foundation of Oral Health

September 8, 2026

By José Melo Barcelos, Vice President of Product, Geltor

Key Takeaways

  • Oral tissues — the mucosa, periodontal ligament, cementum, and dentin — are collagen-dependent structures, with Type 1 collagen as the predominant component in most of them.
  • Aging and inflammation independently compromise this collagen network: aging slows ECM renewal and downregulates key collagen genes, while inflammation upregulates MMPs that degrade collagen directly.
  • Because oral mucosa shares key architectural and functional features with skin, Geltor’s skin efficacy data for HumaColl™21 and PrimaColl® offers a mechanistic rationale for oral care applications.
  • Safety testing in reconstructed human buccal tissue (EpiOral®) showed high tissue viability and low irritation potential, supporting the case for formulating HumaColl™21 and PrimaColl® into oral care products.

Why Oral Tissues Depend on Their Collagen Network and How Biomimetic Collagen Polypeptides Can Support Oral Care Applications

The mouth is one of the body’s most collagen-dependent environments. The tissues that line it and anchor the teeth are collagen-rich connective tissues, and the condition of that collagen network underlies most common oral health concerns. These tissues are under constant challenge: aging slows the renewal of their extracellular matrix (ECM), inflammation accelerates its breakdown, and mechanical injury repeatedly interrupts the barrier they provide.

These challenges converge and surface as some of the most common conditions in oral health. Gingivitis and periodontitis, gum diseases characterized by inflammation of the tissues surrounding the teeth, are the most prevalent. Left unchecked, gingivitis can progress to periodontitis, where that inflammation begins to break down the tooth’s supporting structures. According to the CDC, roughly 4 in 10 U.S. adults aged 30 and older had some level of periodontitis between 2009 and 2014, with prevalence increasing in older age groups (1).

For oral care innovators, this structural dependency presents a key opportunity: supporting the ECM and epithelial barrier is fundamental to next-generation oral wellness. This article reviews how these tissues are built, what erodes them over time, and how Geltor’s biomimetic collagen polypeptides are positioned to support oral care applications.

Oral Mucosa vs. Skin: Architectural Parallels

The oral mucosa is the tissue that lines the oral cavity, and it shares several structures and functions with the skin.

Like skin, it is adapted to protect against mechanical, chemical, and biological insults and to relay sensory information (2).

Its architecture parallels that of skin (Figure 1). The outer layer, the oral epithelium, is composed primarily of keratinocytes and sits on a fibroblast-rich connective tissue layer, the lamina propria, from which it is separated by the basement membrane.

The thickness and degree of keratinization of the oral epithelium vary by location, depending on the functional and mechanical demands placed on each site. The epithelium covering the mobile structures of the mouth is a non-keratinized stratified squamous epithelium, whereas the epithelium covering the masticatory surfaces, such as the gingiva (gums), is keratinized or parakeratinized, allowing it to better withstand the stresses of chewing (2). The masticatory epithelium is subdivided into four layers: the stratum basale, the stratum spinosum, the stratum granulosum, and the stratum corneum (2), the same layers found in the epidermis of thin skin (3).

Labeled diagram comparing the layered structure of skin and oral mucosa side by side: epidermis/oral epithelium, dermis/lamina propria, and subcutis/submucosa-bone, with shared cell types (keratinocytes, fibroblasts, Langerhans cells, collagen I and III) and, on the oral side, the saliva layer and resident bacterial genera (Actinobacteria, Firmicutes, Proteobacteria, Bacteroidetes, Fusobacteria, Spirochaetes).

Figure 1: Comparative architecture of skin and oral mucosa. Redrawn and adapted from Waasdorp et al. (4), Figure 2B (Biomolecules 2021;11(8):1165), licensed under CC BY 4.0.

Collagen in Oral Tissues

Within the lamina propria of the gingiva, fibroblasts are embedded in an extracellular matrix (ECM) that is roughly 60% collagen fibers, with Type 1 collagen being the most abundant (5).

Collagen is just as central to the structures that hold the teeth in place.

The periodontal ligament, which holds the teeth in their sockets and allows them to withstand the forces of mastication, is primarily composed of fibroblasts and an extracellular matrix built from bundles of Type 1, 3, and 12 collagen fibers (6).

Cementum, the hard connective tissue that coats the tooth root and anchors it to the periodontal ligament fibers, has Type 1 collagen as its predominant organic component, making up as much as 90% of its organic matrix (6).

Type 1 collagen is also a major component of dentin and a key structural element in dentin formation (7), providing the scaffold onto which hydroxyapatite is deposited during mineralization.

How Age Affects Oral Tissues

Aging alters a wide range of biological processes. The accumulation of senescent cells and the onset of a chronic inflammatory state, often called inflammaging, are among the hallmarks of aging (8).

In oral tissues, these changes are both structural and functional, and they translate directly into oral health outcomes.

The epithelial layers of the oral mucosa can become thinner, affecting barrier function (8). In the lamina propria, cell density decreases with age (9) and the collagen fibers reorganize into a pattern associated with a fibrotic-like state (10).

Beyond these structural changes to the collagen network, the ECM-synthesizing capacity of fibroblasts also declines with age: expression of ECM-related genes decreases consistently, with a marked downregulation of the COL1A1 and COL3A1 collagen genes (10).

How Inflammation Compromises the Extracellular Matrix

Inflammation of periodontal tissue, which can be triggered by microbial infection and is often aggravated by age, upregulates matrix metalloproteinases (MMPs), enzymes that drive ECM degradation (11), and causes structural modification (12) of the collagen network, compromising the integrity and function of the connective tissues.

This accelerated, MMP-driven collagen degradation can also affect the periodontal ligament, where it can cause loss of the tooth’s supporting tissue (6). In more severe cases, this degradation can lead to gum recession, pain, and even tooth loss.

A healthy, well-organized extracellular matrix is therefore key to keeping the tissues that support the teeth strong and intact.

Barrier Renewal and Tissue Recovery

The oral mucosa is constantly exposed to mechanical stress. Bites, sharp foods, orthodontic appliances, and everyday wear can injure the tissue, opening wounds that temporarily compromise the protective barrier it provides.

Rapid re-epithelialization, which requires migration and proliferation of keratinocytes, is crucial for restoring barrier function and preventing infection. A local infection can trap the wound in an inflammatory state (13), which, as noted earlier, accelerates collagen degradation.

Once the new epithelium has formed, the extracellular matrix must undergo remodeling. This phase restores mechanical strength and shapes the quality of the resulting scar tissue (4).

Supporting the tissue’s natural renewal and matrix-remodeling processes is therefore a meaningful way to help maintain oral tissue integrity.

Biomimetic Collagen Polypeptides to Support a Healthy Oral Foundation

Maintaining oral health relies on an intact epithelial barrier and a strong, well-organized collagen network within the ECM of the oral connective tissues.

HumaColl™21, a biomimetic human Type 21 collagen polypeptide, has been shown to increase the production of multiple ECM components in a full-thickness skin model. In human skin explants (Figure 2), topical application of 0.1% HumaColl™21 increased Type 1 collagen in the dermis by 90% relative to control and raised hyaluronic acid by 546% in the epidermis and 106% in the dermis. It has also been shown to support faster lesion closure and greater neo-epidermis length in a similar ex vivo skin model.

Microscopy comparison of human skin explants, control versus 0.1% HumaColl™21-treated, in a two-row grid: top row shows collagen type I immunofluorescence (green), visibly denser in the treated sample; bottom row shows hyaluronic acid staining (pink), also visibly greater in the treated sample.

Figure 2: Ex vivo study. Skin explants were topically treated with HumaColl™21. After 5 days of treatment, human skin showed significantly higher protein expression of collagen Type 1 (green) and significantly higher expression of HA (pink) in the papillary dermis compared to control.

PrimaColl®, a biomimetic Type 21 collagen polypeptide that shares a high degree of similarity to its human counterpart and is developed for both topical and ingestible applications, has been shown to increase epidermal thickness by promoting cell proliferation and adding keratinocyte layers. In skin explants topically treated with 0.1% PrimaColl®, it also increased Type 1 collagen in the dermis and hyaluronic acid in both the epidermis and dermis, and accelerated wound closure in an in vitro scratch assay.

Microscopy comparison of human skin explants, untreated control versus 0.1% PrimaColl®-treated, in a three-row grid: top row shows collagen type I immunofluorescence (green), denser in the treated sample; middle row shows hyaluronic acid staining (pink), also greater in the treated sample; bottom row shows a cross-section stain comparing epidermal thickness, with a visibly thicker epidermal layer (pink, top band) in the treated sample.

Figure 3: Ex vivo study. Skin explants were topically treated with PrimaColl®. After 4 days of treatment, human skin showed significantly higher protein expression of collagen Type 1 (green) and significantly higher expression of HA (pink) in the papillary dermis compared to the untreated control. Epidermal thickness evaluated after 7 days of treatment.

Across in vitro and ex vivo skin models, Geltor’s biomimetic collagen polypeptides support the biological processes involved in tissue recovery and ECM remodeling. Because skin and oral mucosa share key architectural and functional features, these skin findings provide a compelling proof of mechanism for ECM support and tissue recovery.

Furthermore, safety testing in reconstructed human buccal tissue (EpiOral®, MatTek) demonstrated that high tissue viability and metabolic activity were maintained, indicating low irritation potential. Combined, these findings offer a clear scientific rationale for the use of HumaColl™21 and PrimaColl® in oral care applications.

Partner with Geltor

Ready to elevate your oral care formulations with biomimetic collagen technology? Contact our team at sales@geltor.com to request samples or technical data, or to schedule a call.

José Melo Barcelos, Vice President of Product at Geltor

Written by: José Melo Barcelos, Vice President of Product at Geltor. He holds a degree in chemical engineering from the Universidade de São Paulo and built his product development foundation at L’Oréal before joining Geltor. Today he leads the team responsible for translating Geltor’s biodesigned proteins into commercially ready ingredients for formulators.

 

References
  1. About Periodontal (Gum) Disease. U.S. Centers for Disease Control and Prevention [Internet]. 2024 May 15 [cited 2026 Jul 27]. Available from: https://www.cdc.gov/oral-health/about/gum-periodontal-disease.html
  2. Brizuela M, Winters R. Histology, Oral Mucosa. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2026 Jul 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK572115/
  3. Yousef H, Alhajj M, Fakoya AO, Sharma S. Anatomy, Skin (Integument), Epidermis. In: StatPearls [Internet]. StatPearls Publishing; 2024 [cited 2026 Jul 30]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470464/
  4. Waasdorp M, Krom BP, Bikker FJ, van Zuijlen PPM, Niessen FB, Gibbs S. The Bigger Picture: Why Oral Mucosa Heals Better Than Skin. Biomolecules. 2021 Aug 6;11(8):1165. https://doi.org/10.3390/biom11081165
  5. Koller A, Sapra A. Anatomy, Head and Neck, Oral Gingiva. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2026 Jul 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560662/
  6. Nanci A, Bosshardt DD. Structure of periodontal tissues in health and disease. Periodontol 2000. 2006 Feb;40(1):11–28. https://doi.org/10.1111/j.1600-0757.2005.00141.x
  7. Goldberg M, Kulkarni AB, Young M, Boskey A. Dentin: structure, composition and mineralization. Front Biosci. 2011 Jan 1;3(2):711–35. https://doi.org/10.2741/e281
  8. Qiu C, Jie W, Qian Y, Lu X, Chen Y, Si M. Ageing of the Oral Mucosa: Mechanisms and Consequences. Int Dent J. 2026 Jun;76(3):109482. https://doi.org/10.1016/j.identj.2026.109482
  9. Ryan EJ, Toto PD, Gargiulo AW. Aging in Human Attached Gingival Epithelium. J Dent Res. 1974 Jan;53(1):74–6. https://doi.org/10.1177/00220345740530013501
  10. Cecchin-Albertoni C, Deny O, Pieruccioni L, Ousset M, Oreja-Fuentes P, Arnaud E, et al. Age-related evolution of human gingiva towards a fibrotic-like connective phenotype. Sci Rep. 2025 Nov 25;15(1):45298. https://doi.org/10.1038/s41598-025-29089-w
  11. Radzki D, Negri A, Kusiak A, Obuchowski M. Matrix Metalloproteinases in the Periodontium—Vital in Tissue Turnover and Unfortunate in Periodontitis. Int J Mol Sci. 2024 Feb 27;25(5):2763. https://doi.org/10.3390/ijms25052763
  12. Chandran A, Bhandary R, Shenoy N, Shetty UA. Analysis of collagen fibers in human gingival tissues using picrosirius red stain under polarized microscope. J Indian Soc Periodontol. 2021;25(2):106–11. https://doi.org/10.4103/jisp.jisp_152_20
  13. Politis C, Schoenaers J, Jacobs R, Agbaje JO. Wound Healing Problems in the Mouth. Front Physiol. 2016;7:507. https://doi.org/10.3389/fphys.2016.00507
Disclaimer
This article/media is intended for general educational and informational purposes. It does not constitute medical advice and is not intended to diagnose, treat, cure, or prevent any disease. Statements regarding specific ingredients reflect current scientific understanding and have not been evaluated by the FDA. Individual results may vary.